1. Residual CVD Risk Niacin and Simvastatin P. Pauletto Medicina Interna I^, Treviso University of Padova - Italy

3. Time to the first primary clinical end point (death from coronary causes, nonfatal MI, stroke, or revascularization) Brown BG et al. N Engl J Med 2001;345:1583

4. Stenosis (%) and minimal luminal diameter for nine proximal lesions, for all lesions, and for lesions in various categories of base-line severity, according to treatment group. Brown BG et al. N Engl J Med 2001;345:1583

5. Dose ranges and efficacy of statins, ezetimibe, and bile acid sequestrants Runhua H et al. Endocrinol Metab Clin N Am 2009;38:79

6. Residual CVD Risk After Statin Therapy Alagona P. Am J Manag Care 2009;15:s65

7. Low HDL-C Is Associated With High CVD Risk Even If LDL-C Levels Are Well-Controlled (TNT Study) Alagona P. Am J Manag Care 2009;15:s65

8. Strategies for Reducing CHD Risk Alagona P. Am J Manag Care 2009;15:s65

9. Efficacy of niacin ER/simvastatin combination therapy: SEACOAST I Alagona P. Am J Manag Care 2009;15:s65

10. Efficacy of niacin ER/simvastatin combination therapy: SEACOAST II Alagona P. Am J Manag Care 2009;15:s65

11. Fenofibric Acid and Rosuvastatin Combination Therapy in Patients With Mixed Dyslipidemia Alagona P. Am J Manag Care 2009;15:s65